C-Kit is mutated in approximately 15–20% of acral and mucosal melanomas (Beadling et al, 2008; Satzger et al, 2008; Torres-Cabala et al, 2009), and marked objective tumour responses have been observed in patients with exon 11 and exon 13 c-Kit mutant melanoma treated with dasatinib. This evidence concerns the gene KIT and melanoma.